Best lung-specific organ response while on ruxolitinib, according to lung score at enrollment
| NIH lung score at baseline . | Number of evaluable participants . | CR rate∗ . | PR rate∗ . | Best ORR∗ . |
|---|---|---|---|---|
| 1 | 15 | 26.7% (n = 4) | 13.3% (n = 2) | 40% (n = 6) |
| 2 | 26 | 11.5% (n = 3) | 26.9% (n = 7) | 38.5% (n = 10) |
| 3 | 8 | 12.5% (n = 1) | 0% (n = 0) | 12.5% (n = 1) |
| Total | 49 | 16.3% (n = 8) | 18.4% (n = 9) | 34.7% (n = 17) |
| NIH lung score at baseline . | Number of evaluable participants . | CR rate∗ . | PR rate∗ . | Best ORR∗ . |
|---|---|---|---|---|
| 1 | 15 | 26.7% (n = 4) | 13.3% (n = 2) | 40% (n = 6) |
| 2 | 26 | 11.5% (n = 3) | 26.9% (n = 7) | 38.5% (n = 10) |
| 3 | 8 | 12.5% (n = 1) | 0% (n = 0) | 12.5% (n = 1) |
| Total | 49 | 16.3% (n = 8) | 18.4% (n = 9) | 34.7% (n = 17) |
Response according to 2014 NIH consensus criteria using percent predicted FEV1 evaluations alone.